Website stats for Keytruda - keytruda.com
KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen an...
keytruda.com was registered 1 decade 3 years ago. It has a alexa rank of #365,256 in the world. It is a domain having .com extension. It is estimated worth of $ 25,380.00 and have a daily income of around $ 47.00. As no active threats were reported recently, keytruda.com is SAFE to browse.
Traffic Report
| Daily Unique Visitors: | 4,201 |
| Daily Pageviews: | 16,804 |
Estimated Valuation
| Income Per Day: | $ 47.00 |
| Estimated Worth: | $ 25,380.00 |
Search Engine Indexes
| Google Indexed Pages: | Not Applicable |
| Yahoo Indexed Pages: | Not Applicable |
| Bing Indexed Pages: | Not Applicable |
Search Engine Backlinks
| Google Backlinks: | Not Applicable |
| Bing Backlinks: | Not Applicable |
| Alexa BackLinks: | Not Applicable |
Safety Information
| Google Safe Browsing: | No Risk Issues |
| Siteadvisor Rating: | Not Applicable |
| WOT Trustworthiness: |
 Very Poor
|
| WOT Privacy: |
Very Poor
|
| WOT Child Safety: |
Very Poor
|
Website Ranks & Scores
| Alexa Rank: | 365,256 |
| PageSpeed Score: | 89 ON 100 |
| Domain Authority: |
49 ON 100 
|
| Bounce Rate: | Not Applicable |
| Time On Site: | Not Applicable |
Web Server Information
Hosted IP Address:
13.224.99.101
Hosted Country:
CH
Location Latitude:
47.3667Location Longitude:
8.55Traffic Classification
| Total Traffic: | 1.00M |
| Direct Traffic: | 11.10% |
| Referral Traffic: | 4.68% |
| Search Traffic: | 62.64% |
| Social Traffic: | 1.76% |
| Mail Traffic: | 1.97% |
| Display Traffic: | 17.84% |
Search Engine Results For keytruda.com
Keytruda: Side effects, uses, cost, and more - Medical News Today
16 Feb 2020 ... Keytruda contains the drug pembrolizumab. It belongs to a class of drugs called PD-1 inhibitors. Keytruda is an immunotherapy drug, which means ...
FDA Approves Keytruda (Pembrolizumab) for Any Tumor with ...
24 May 2017 ... The US Food and Drug Administration (FDA) has expanded the approval of the immunotherapy drug Keytruda (pembrolizumab) to include tumors ...
Weekly Dose: Keytruda may be a miracle cancer drug, but can those ...
11 Apr 2018 ... Keytruda (generic name pembrolizumab) is an immunotherapy drug manufactured by the company Merck & Co. It is most commonly used to treat ...
KEYTRUDA® (pembrolizumab) | Access Program for Health Care ...
... care professionals answer questions about insurance coverage and reimbursement support for eligible patients prescribed KEYTRUDA® (pembrolizumab).
Pembrolizumab - Wikipedia
Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck ...
FDA Approves Expanded Indication for Merck's KEYTRUDA ...
6 Jul 2021 ... KEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect ...
Medicare Coverage for Keytruda - Healthline
27 Aug 2020 ... Does Medicare Cover Keytruda? · Keytruda (pembrolizumab) is an FDA-approved immunotherapy treatment for cancer. · Medicare Part B covers Keytruda ...
Keytruda (Pembrolizumab) - Mesothelioma Immunotherapy Drug
In May 2017, the FDA approved Keytruda in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer. Keytruda is also ...
How KEYTRUDA® (pembrolizumab) and LENVIMA® (lenvatinib ...
KEYTRUDA and LENVIMA are two different kinds of medicines that you use together to help treat your advanced endometrial cancer. KEYTRUDA: How does it work?
Keytruda - US Food and Drug Administration
KEYTRUDA, as a single agent, is indicated for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA- ...
KEYTRUDA® (pembrolizumab)
KEYTRUDA is not chemotherapy or radiation therapy—it is an immunotherapy and it works with your immune system to help fight cancer. KEYTRUDA can cause your ...
Keytruda: a new generation of cancer treatment - LifeArc
Our antibody engineering service has successfully humanised more than 65 antibodies, including the immunotherapy treatment Keytruda.
Pembrolizumab for Advanced MSI-H/dMMR Cancers - AIM with ...
- http://aimwithimmunotherapy.org/wp-content/uploads/2018/10/Pembro-MSI-High-Toolkit-Final.pdf
Pembrolizumab (Keytruda®) is an anti-programmed death receptor-1 (PD-1) monoclonal antibody checkpoint inhibitor. PD-1 is a negative regulator of T-cell ...
FDA Approves Expanded Indication for Merck's ... - Bloomberg.com
6 Jul 2021 ... FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) in Locally Advanced Cutaneous Squamous Cell Carcinoma (cSCC) KEYTRUDA ...
Keytruda (pembrolizumab): Side Effects, How it Works, and More
4 Jan 2021 ... Keytruda also may be used to treat: metastatic or unresectable breast cancers that have a biomarker called microsatellite instability-high (MSI- ...
Pembrolizumab (KEYTRUDA, Merck & Co.) – all entries with PAPs ...
Keytruda (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & co Inc.; 2017. U.S. Food and Drug Administration. FDA approves first cancer treatment ...
Patricia Guttenbeil talks about Keytruda and lung cancer - YouTube
Patricia Guttenbeil talks about Keytruda and lung cancer. 1,991 views1.9K views. May 6, 2019. 13. 2. Share. Save. 13 / 2.
New Dosing Schedule Approved for All Keytruda Indications - MPR
30 Apr 2020 ... The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage ...
FoundationOne®CDx Receives FDA Approval as the First ...
17 Jun 2020 ... KEYTRUDA is now approved for two pan-tumor indications. In 2017, KEYTRUDA was granted FDA approval as the first cancer treatment based on a ...
Pembrolizumab (Keytruda®) - Melanoma Research Alliance
Pembrolizumab (Keytruda®) is an immunotherapy medication for advanced melanoma that stimulates the immune system to fight cancer cells throughout the body.
pembrolizumab (Keytruda) - Scottish Medicines Consortium
9 Sept 2019 ... a full submission assessed under the end of life medicine process: pembrolizumab (Keytruda®) is accepted for restricted use within NHSScotland.
Pembrolizumab (Keytruda) - Drug Information | Chemocare
Pembrolizumab is the generic name for the trade drug name Keytruda®. In some cases, health care professionals may use the generic name pembrolizumab when ...
Page Resources Breakdown
Homepage Links Analysis
Website Inpage Analysis
| H1 Headings: | 1 | H2 Headings: | 6 |
| H3 Headings: | 5 | H4 Headings: | 6 |
| H5 Headings: | 1 | H6 Headings: | Not Applicable |
| Total IFRAMEs: | Not Applicable | Total Images: | 26 |
| Google Adsense: | Not Applicable | Google Analytics: | Not Applicable |
Two Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| may be | 28 | 0.765 % | No |
| It may | 26 | 0.71 % | No |
| be used | 26 | 0.71 % | No |
| when your | 20 | 0.546 % | No |
| you have | 19 | 0.519 % | No |
| kind of | 17 | 0.464 % | No |
| a kind | 17 | 0.464 % | No |
| cancer has | 17 | 0.464 % | No |
| cancer called | 16 | 0.437 % | No |
| has spread | 16 | 0.437 % | No |
| not work | 14 | 0.383 % | No |
| did not | 14 | 0.383 % | No |
| by surgery | 14 | 0.383 % | No |
| cannot be | 13 | 0.355 % | No |
| and it | 13 | 0.355 % | No |
| treatment and | 13 | 0.355 % | No |
| work or | 13 | 0.355 % | No |
| it did | 13 | 0.355 % | No |
| cancer metastatic | 12 | 0.328 % | No |
| metastatic advanced | 12 | 0.328 % | No |
Four Phrase Analysis
| Words | Occurrences | Density | Possible Spam |
|---|---|---|---|
| It may be used | 25 | 0.683 % | No |
| it did not work | 13 | 0.355 % | No |
| did not work or | 13 | 0.355 % | No |
| and it did not | 12 | 0.328 % | No |
| be removed by surgery | 11 | 0.301 % | No |
| cannot be removed by | 11 | 0.301 % | No |
| is no longer working | 10 | 0.273 % | No |
| work or is no | 9 | 0.246 % | No |
| not work or is | 9 | 0.246 % | No |
| be used when your | 9 | 0.246 % | No |
| cancer has spread or | 9 | 0.246 % | No |
| may be used when | 9 | 0.246 % | No |
| or is no longer | 9 | 0.246 % | No |
| a kind of cancer | 8 | 0.219 % | No |
| tests positive for “PDL1” | 8 | 0.219 % | No |
| has spread or cannot | 8 | 0.219 % | No |
| spread or cannot be | 8 | 0.219 % | No |
| or cannot be removed | 8 | 0.219 % | No |
| use is approved based | 7 | 0.191 % | No |
| This use is approved | 7 | 0.191 % | No |
Websites Hosted on Same IP (i.e. 13.224.99.101)
Open Data Kit
Open Data Kit began with a vision to make open-source mobile data collection software for resource-limited settings. Over the last 13 years, the project has produced two tool...
1,036,664 
$ 1,200.00
Used & New Heavy Industrial Machines, Machinery & Equipment for...
Used and New Industrial Machines & Equipment on sale at Machines4u Australia's No. 1 Online Machinery Trader Classifieds. Sell your new or second hand heavy machinery &...
128,638 $ 97,200.00
Church Giving: Mobile App, Online & Text Giving for Churches |...
Looking to accept online donations for church? Tithe.ly is a free church giving app for all your mobile giving & online giving needs. ✓ Click to try today!
72,487 $ 208,800.00
Home - SiFive
SiFive is the first fabless semiconductor company to build customized silicon based on the free and open RISC-V instruction set architecture.
448,654 $ 9,360.00
HTTP Header Analysis
Status-Code: 200
Status: 200 OK
Content-Type: text/html
Transfer-Encoding: chunked
Connection: keep-alive
x-amz-id-2: hJ5WjMG5xfp/WCQCxPWwjmDQADFFPZsHe5UxpS7WcpVj6uvLfVYc/ubojxa/rAFmKSq46s hrWk=
x-amz-request-id: QD22CVGTEWTSBGFW
Last-Modified: Mon, 12 Jul 2021 22:15:36 GMT
x-amz-server-side-encryption: AES256
Server: AmazonS3
Content-Encoding: gzip
Date: Wed, 21 Jul 2021 14:52:17 GMT
ETag: W/"15d4b7fce956add71f6667ec1bfc404b"
Vary: Accept-Encoding
X-Cache: Hit from cloudfront
Via: 1.1 a2037d86ccb1a548f20827ebd95a65f3.cloudfront.net (CloudFront)
X-Amz-Cf-Pop: ZRH50-C1
X-Amz-Cf-Id: HxyFCikSihizUHkRq0KQwM-ysnNe33XuVs_4aeK444nY4W6CAcztxg==
Age: 159
Domain Information
| Domain Registrar: |
MarkMonitor Inc.
|
|---|---|
| Registration Date: | 2011-11-11 1 decade 3 years 1 week ago |
| Last Modified: | 2020-10-10 4 years 1 month 6 days ago |
Domain Nameserver Information
| Host | IP Address | Country | |
|---|---|---|---|
| ns-1162.awsdns-17.org | |
205.251.196.138 |  United States |
| ns-1662.awsdns-15.co.uk | |
205.251.198.126 | United States |
| ns-439.awsdns-54.com | |
205.251.193.183 | United States |
| ns-793.awsdns-35.net | |
205.251.195.25 | United States |
DNS Record Analysis
| Host | Type | TTL | Extra |
|---|---|---|---|
| keytruda.com | A | 297 |
IP: 13.224.99.4 |
| keytruda.com | A | 297 |
IP: 13.224.99.101 |
| keytruda.com | A | 297 |
IP: 13.224.99.25 |
| keytruda.com | A | 297 |
IP: 13.224.99.52 |
| keytruda.com | NS | 86400 |
Target: ns-1162.awsdns-17.org |
| keytruda.com | NS | 86400 |
Target: ns-1662.awsdns-15.co.uk |
| keytruda.com | NS | 86400 |
Target: ns-439.awsdns-54.com |
| keytruda.com | NS | 86400 |
Target: ns-793.awsdns-35.net |
| keytruda.com | SOA | 900 |
MNAME: ns-793.awsdns-35.net RNAME: awsdns-hostmaster.amazon.com Serial: 1 Refresh: 7200 Retry: 900 Expire: 1209600 |
| keytruda.com | TXT | 300 |
TXT: qwd0c4831r6zm6yqbt5spl24gm1s0t1l |
| keytruda.com | TXT | 300 |
TXT: facebook-domain-verification=1w9baezb6x4 b7kizbnxvebuj54paex |
| keytruda.com | TXT | 300 |
TXT: google-site-verification=cosbXYCVIsqhPNf FUwE_Ll-wNrulH4ZuM6iz5-qnoaU |
| keytruda.com | TXT | 300 |
TXT: google-site-verification=xtjuVqWgjkbF9-X 7cY9RapL9ocqZ4DTZJW1yrhwIq5g |
Top Organic Keyword
| 1. | keytruda |
| 2. | pembrolizumab |
| 3. | keytruda side effects |
| 4. | keytruda cost |
| 5. | skin cancer |
Top Paid Keyword
| 1. | keytruda |
| 2. | pembrolizumab |
| 3. | keytruda package insert 2021 |
| 4. | keytruda package insert |
| 5. | skin cancer lesions |
Top Referral Site
| 1. | keytrudahcp.com |
| 2. | notabler.livejournal.com |
| 3. | tigernet.com |
Top Destination Site
| 1. | keytrudahcp.com |
| 2. | merck.com |
Full WHOIS Lookup
Registry Domain ID:
1686641663_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.markmonitor.com
Registrar URL:
http://www.markmonitor.com
Updated Date:
2020-10-10T09:08:24Z
Creation Date:
2011-11-11T11:45:48Z
Registry Expiry Date:
2022-11-11T11:45:48Z
Registrar: MarkMonitor Inc.
Registrar
IANA ID: 292
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
+1.2083895740
Domain Status: clientDeleteProhibited
https://icann.org/epp#clientDeleteProhibited
Domain Status:
clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Domain Status:
clientUpdateProhibited
https://icann.org/epp#clientUpdateProhibited
Name Server:
NS-1162.AWSDNS-17.ORG
Name Server:
NS-1662.AWSDNS-15.CO.UK
Name Server: NS-439.AWSDNS-54.COM
Name
Server: NS-793.AWSDNS-35.NET
DNSSEC: unsigned
URL of the ICANN
Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>>
Last update of whois database: 2021-07-21T14:54:48Z
Similarly Ranked Websites
Archer Hotel | Boutique Hotels | Home
Say 'yes' to new adventures. Your room is ready in Archer's boutique hotels in New York, Austin and Napa. Make plans to visit Burlington and Florham Park soon.
365,258 $ 25,380.00
مدرسة المصممين - بوابتك لعالم الإبداع
مدرسة المصممين هي عبارة عن شبكه تعليميه متعددة الخدمات متخصصة فى مجالات: التصميم الجرافيكي & الملتيميديا، وتمدك بأدوات التصميم ومعلومات هامة في صورة مقالات.
365,262 $ 25,380.00
1x2 Betting Tips | Sure 1x2 Betting | 1x2 bet tips
1x2 Betting Tips | Sure 1x2 Betting | 1x2 bet tips | 1x2 Betting Tips best daily tips KING IS BACK paid professional soccer tipster soccer predictions 1×2, soccer predictions...
365,265 $ 25,380.00
www.congo-liberty.com | POUR UN CONGO LIBRE ET DEMOCRATIQUE: SASSOU...
365,265 $ 25,380.00